Nutrition.ad Nutrition.ad
Nutrition News

FDA Signals Shift on Dietary Supplement Warnings as Oversight Gaps Persist

Regulatory moves in Washington collide with a fast-growing global supplements market and longstanding safety concerns.

FDA Signals Shift on Dietary Supplement Warnings as Oversight Gaps Persist
#dietary supplements#FDA regulation#public health#clinical trials#consumer safety

FDA Signals Shift on Dietary Supplement Warnings as Oversight Gaps Persist

The U.S. Food and Drug Administration is considering loosening its warning-label requirements for dietary supplements even as public health researchers and regulators at home and abroad highlight persistent gaps in safety oversight and clinical evidence for a market projected to nearly double in value by 2028.

An agency spokesperson confirmed this month that the FDA may relax certain supplemental warning-label rules, according to reporting by NBC News, a move that could affect products heavily promoted by public figures aligned with the “Make America Healthy Again” movement, including Centers for Medicare and Medicaid Services administrator Mehmet Oz, who faced criticism during his confirmation hearing for calling some supplements “magic” weight-loss aids.1

The potential shift comes as Congress weighs the Dietary Supplement Regulatory Uniformity Act, a preemption bill that could curb states’ ability to restrict or ban specific ingredients based on local safety concerns or emerging science when the FDA has not acted at the federal level, legal analysts reported.2

Fast-growing global market under light-touch U.S. rules

The global dietary supplements market was valued at about $152 billion in 2021 and is expected to reach $300 billion by 2028, according to a 2023 review in the Journal of Dietary Supplements that examined regulation, market trends, COVID-era use and health effects worldwide.3

In the United States, dietary supplements are regulated more like foods than drugs under the 1994 Dietary Supplement Health and Education Act (DSHEA). Manufacturers do not need to prove efficacy or conduct clinical trials before marketing products, and ingredients sold before October 15, 1994, are generally presumed safe—“grandfathered” as generally recognized as safe (GRAS)—without prior FDA evaluation, a review in Current Drug Safety noted.4

A widely cited public health analysis published in the Annual Review of Public Health described federal oversight of supplements as “too little, too late,” arguing that the reactive, post-market structure has proved ineffective at preventing harms.5

FDA relies on post-market tools, older rulemaking

FDA guidance and regulatory documents underscore that the agency’s role is largely to police the marketplace after products reach consumers. The agency issues warning letters, coordinates recalls, and publishes public notices when products present “a significant or serious risk,” though not all recalls trigger press releases or website postings, according to its “What’s New in Dietary Supplements” portal.6

Labeling of health claims, nutrient content claims and “statements of nutritional support” is governed by a 1997 final rule on food labeling for dietary supplements, which still underpins much of the current claims framework.7 Under this regime, companies may make structure/function claims—such as “supports immune health”—but must avoid disease-treatment claims and include the familiar disclaimer that the FDA has not evaluated the statement.

Manufacturers are responsible for product quality under current good manufacturing practices (cGMPs) in 21 CFR Part 111, which require consistent production, quality control and documentation for supplements, regulatory consultants note.8 However, FDA inspections and enforcement resources remain limited relative to the size of the industry.

The National Academies of Sciences, Engineering, and Medicine in 2005 called on FDA to adopt a “cost-effective and scientifically sound” framework for continuously evaluating supplement ingredient safety, emphasizing the need to track evolving use patterns and potential interactions with drugs and other substances.9

Proposed federal preemption raises state–federal tensions

States have sometimes moved faster than federal regulators to restrict ingredients such as certain stimulants or weight-loss compounds, citing local safety data or enforcement priorities. The Dietary Supplement Regulatory Uniformity Act, analyzed by food-and-drug law attorneys this year, would significantly narrow that state-level autonomy by expanding federal preemption.2

Under the bill, new or stricter state prohibitions on ingredients could face heightened legal challenges if FDA has not taken equivalent action. Supporters argue that a patchwork of state rules burdens manufacturers and confuses consumers, while critics warn it could weaken an important layer of consumer protection where federal oversight is slow or absent.

A 2024 industry safety paper from the Consumer Healthcare Products Association outlined how firms navigate GRAS determinations, new dietary ingredient (NDI) notifications and expert safety reviews under current law, but also highlighted the complexity and variability of premarket safety submissions relative to drug approvals.10

Safety concerns and documented adverse effects

Despite widespread use, evidence of harm from some supplements continues to accumulate. A review of adverse effects of nutraceuticals and dietary supplements, published in Frontiers in Pharmacology, underscored that many products reach the market without preclinical toxicology or human trials and can cause liver injury, cardiovascular events and drug–supplement interactions.4

The authors noted that “no clinical trials are required” before marketing a supplement and warned that the comparatively lenient safety requirements “may give the impression of safety that is not always justified.”4 The article called for more stringent premarket evaluation and improved surveillance of adverse events.

Public health scholars have similarly argued that DSHEA’s structure leaves FDA largely dependent on voluntary manufacturer reporting and post-market signals such as poison center data, hospitalizations or high-profile incidents, rather than proactive risk assessment.5

Clinical trials struggle to keep up with complex products

When supplement makers or independent researchers do pursue clinical trials, they face distinctive methodological challenges, according to a detailed 2021 guidance article in Frontiers in Nutrition.11 Botanical extracts, for example, may contain dozens of active compounds whose composition can vary by batch, complicating dosing, blinding, and reproducibility.

The authors stressed that nutrition and supplement trials often contend with background diet, adherence, and long latency periods for health outcomes. They recommended more rigorous standardization of products, better characterization of active components, and transparent reporting of negative findings.11

A separate review of clinical trial regulation in the U.S. emphasized that when supplements are studied for disease treatment or prevention, protocols may fall under investigational new drug requirements, bringing them closer to drug trial standards. Otherwise, food and supplement studies operate within a more flexible, but less stringent, regulatory framework overseen by FDA and institutional review boards.12

At the same time, researchers are exploring advanced tools—such as nutrigenomics, microbiome analysis, artificial intelligence and machine learning—to clarify which supplement ingredients exert biological effects and in whom, according to an overview in the Journal of Nutrition describing the “evolution of science” in the field.13

International regulators tighten nutrient limits and claims

Outside the U.S., regulators have moved to more tightly define what can be sold as a supplement and what can be said on labels.

In the European Union, Directive 2002/46/EC sets EU-wide rules for food supplements, including lists of permitted vitamins and minerals and controls on claims intended to protect consumers “against potential health risks” and misleading information, the European Commission notes.14

Brazil’s National Health Surveillance Agency (ANVISA) defines food supplements as products intended to supplement the normal diet with specific nutrients and bioactive substances, and explicitly requires proof of safety and quality. ANVISA distinguishes supplements from medicines and enforces compositional limits, labeling rules and notification or registration pathways depending on the product category, according to regulatory summaries.15

A comparative analysis by the Food and Drug Law Institute found that regulatory regimes in the U.S. and abroad are “constantly changing to ensure product safety and compliance,” with some jurisdictions—particularly in the EU—taking a more restrictive approach to allowable ingredients, maximum levels and health claims than the U.S. system.16

Industry braces for shifting rules through 2026

Consultants tracking dietary supplement manufacturing trends predict that enforcement of cGMPs under 21 CFR Part 111 will intensify through 2026, pushing companies toward greater documentation, testing and supply-chain control even if labeling rules ease.8

Yet with market growth continuing, public health experts say the fundamental tension remains: supplements sit between foods and drugs, but are regulated as the former while often marketed closer to the latter. As FDA weighs changes to warning labels and Congress considers further preemption of state authority, researchers and advocates are watching to see whether the next wave of regulatory reform closes long-criticized safety gaps—or further constrains efforts to control risky products.

References & Links

Footnotes

  1. “FDA says it may relax warning label rule for dietary supplements,” NBC News. ↩ ↩2

  2. “The Dietary Supplement Regulatory Uniformity Act: Key Preemption Issues,” JD Supra legal analysis. ↩ ↩2 ↩3

  3. “A Global Overview of Dietary Supplements: Regulation, Market Trends, Usage during the COVID-19 Pandemic, and Health Effects,” summarized by Journalists’ Resource. ↩ ↩2

  4. “Adverse Effects of Nutraceuticals and Dietary Supplements,” Frontiers in Pharmacology (PMC). ↩ ↩2 ↩3 ↩4

  5. “Too Little, Too Late: Ineffective Regulation of Dietary Supplements in the United States,” Annual Review of Public Health (PMC). ↩ ↩2 ↩3

  6. “What’s New in Dietary Supplements,” FDA. ↩ ↩2

  7. “Food Labeling; Requirements for Nutrient Content Claims, Health Claims, and Statements of Nutritional Support for Dietary Supplements,” FDA final rule (September 1997). ↩ ↩2

  8. “Dietary Supplement Trends 2026: GMP & Manufacturing Impact,” cGMP Consulting. ↩ ↩2 ↩3

  9. Dietary Supplements: A Framework for Evaluating Safety, National Academies of Sciences, Engineering, and Medicine (2005). ↩ ↩2

  10. “Safety Considerations for Dietary Supplement Manufacturers in the U.S.,” Consumer Healthcare Products Association (2024). ↩ ↩2

  11. “Designing a Clinical Study With Dietary Supplements,” Frontiers in Nutrition / NIH PMC. ↩ ↩2 ↩3

  12. “Food and Dietary Supplements Clinical Trials Regulations in USA,” ProRelix Research. ↩ ↩2

  13. “The Evolution of Science and Regulation of Dietary Supplements,” Journal of Nutrition. ↩ ↩2

  14. “Food Supplements,” European Commission, Food Safety. ↩ ↩2

  15. “Nutraceutical and Dietary Supplements Regulations in Brazil,” Artixio. ↩ ↩2

  16. “Comparing Dietary Supplement Regulations in the U.S. and Abroad,” Food and Drug Law Institute. ↩ ↩2

Back to News